Shakeel Shareef, MD
Ophthalmology · Reston, VANPI 1366475378
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (60.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Alcon accounts for 66.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $607 and has fallen 94.3% since, to $35 in 2025.
Across 20 payments — averaging $62.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$838
- Ivantis, Inc$256
- AbbVie$53
- Johnson & Johnson Surgical Vision, Inc.$38
- NEW World Medical,inc.$35
- Alimera Sciences, Inc.$21
- plus $16 from 1 others
What the payments were for
- Consulting fees$15012%
- Travel & lodging$35328%
- Food & beverage$75460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $838 |
| Ivantis, Inc | 2 | $256 |
| AbbVie(2 entities) | 3 | $53 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $38 |
| NEW World Medical,inc. | 1 | $35 |
| Alimera Sciences, Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ VIVITY IOL$150
- AcrySof IQ PanOptix$150
- Hydrus$150
- Clareon$119
- Hydrus Microstent$106
How this compares
$1,256 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 68 | $3,188 |
| Latanoprost | 110 | $1,108 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $1,098 |
| Ofloxacin | 71 | $678 |
| Dorzolamide Hcl | 28 | $437 |
| Timolol Maleate | 11 | $213 |
| Brimonidine Tartrate | 15 | $134 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Reston
- Soheila RostamiReston$73K
- Andrew SiegelReston$12K
- Jacqueline GriffithsReston$8K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.